LOG-AFTER software to improve long-term monitoring of childhood cancer survivors
Official title: LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) / Etude d'Impact du Logiciel LOG-AFTER Sur le Suivi à Long Terme Des Anciens Patients (LOG-I - LOG-Impact Study)
Run by University Hospital, Angers · NCT06939322 · Data updated 2026-11-12
This project will test whether giving childhood cancer survivors access to the LOG-AFTER app (with optional GP linkage) helps them follow recommended long-term screenings.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 15 Years and up |
| Sex | All |
| Enrollment | 320 (estimated) |
| Sponsor | University Hospital, Angers Government |
| Locations | 1 site (Angers, Maine Et Loire) |
| Status | Recruiting |
| Started | June 6, 2025 |
| Main results expected | November 6, 2026 |
| Study ends | June 6, 2030 |
| Registry record updated | July 2, 2025 |
| Trial ID | NCT06939322 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are survivors treated for cancer or malignant hematologic disease before age 25 who are disease-free or stable without treatment for at least 5 years, have three or more recommended screenings in their survivorship plan, have internet access on a computer or smartphone/tablet, and can give informed consent.
✕Probably not a fit
Patients unlikely to benefit include those with a relapse or second cancer within the past 5 years, people without internet access or health insurance, and those under legal protection or deprived of liberty.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized interventional comparison where survivors are assigned to follow-up with or without access to the LOG-AFTER software. For participants given access, an account is created within five days of the visit and their personalized after-cancer plan (PPAC) is recorded; all participants complete the PAM-13 patient activation questionnaire. The system collects treatment history, late-effect and psychosocial data, and can notify the patient’s general practitioner when activated. The main aim is to compare how the digital tool affects adherence to recommended survivorship screenings and patient activation over routine follow-up.
Why it matters
Potential benefit: If successful, LOG-AFTER could increase adherence to recommended screenings, improve patient activation, and help detect late complications earlier.
How similar studies have gone: Previous digital survivorship and e-health programs have shown modest improvements in follow-up adherence and patient activation, while LOG-AFTER’s radiotherapy details and GP linkage represent a relatively novel combination.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Previously treated for cancer or malignant hematological pathology before the age of 25 * Without residual disease or with a stable disease without treatment for 5 years or more * Owning a computer, smartphone or equivalent I-Pad/tablet with internet access * Having signed the consent (or their parents if the patient is a minor, or a third party if necessary) * Having 3 or more recommended screenings in their survivorship care plan * No access created to LOG-AFTER before the study or having never connected after opening their account if opening an account dating back 24 months or more at the time of inclusion Exclusion Criteria: * Patient who has relapsed or developed a second cancer with a post-treatment delay \< 5 years * Patient not covered by a health insurance * Patient subject to a legal protection measure, patient deprived of liberty by judicial or administrative decision, patient subject to psychiatric care under duress
Where it's running
-
University Hospital of Angers
Angers, Maine Et Loire, France Recruiting
Study contacts
- Principal investigator: Charlotte DEMOOR-GOLDSCHMIDT, Dr — University Hospital of Angers
- Study coordinator: Sandra MERZEAU
- Email: samerzeau@chu-angers.fr
- Phone: (+33)2 41 35 59 70
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FaceSay: a computer program to help kids recognize facial expressions and improve social interactions
A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.
-
Personalized exercise plan for cancer survivors
This study tests a personalized, physician-guided exercise program for adults who have completed cancer treatment, to see if a safe, structured plan can be implemented in routine care.
-
Access to Innovative Cancer Treatments for Children and Young People in Belgium
This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.
-
BCB-276 CAR T therapy for DIPG in children and young adults
This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.
-
CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes
This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.
-
Virtual reality headsets to reduce anxiety and fear during intrathecal chemotherapy in children
This project will try virtual reality headsets with children aged 4–10 who are receiving intrathecal chemotherapy to see if they reduce anxiety, fear, and changes in vital signs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.